Matthew Blischak
Chief Executive Officer bei FINCH THERAPEUTICS GROUP, INC.
Profil
Matthew P.
Blischak is currently the President, Chief Executive Officer & Secretary at Finch Therapeutics Group, Inc. Prior to his current position, he worked as the Vice President-Intellectual Property at Roivant Sciences, Inc. from 2018 to 2023.
Mr. Blischak completed his undergraduate degree at Case Western Reserve University and his graduate degrees at The Johns Hopkins University and American University Washington College of Law.
Aktive Positionen von Matthew Blischak
| Unternehmen | Position | Beginn |
|---|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Chief Executive Officer | 16.05.2023 |
Ehemalige bekannte Positionen von Matthew Blischak
| Unternehmen | Position | Ende |
|---|---|---|
Roivant Sciences, Inc.
 Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Corporate Officer/Principal | 01.04.2023 |
Ausbildung von Matthew Blischak
| Case Western Reserve University | Undergraduate Degree |
| The Johns Hopkins University | Graduate Degree |
| American University Washington College of Law | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Health Services |
| Private Unternehmen | 1 |
|---|---|
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Health Technology |
